Track market-moving stories before they get noisy

On July 24, 2026, Service Corp International (SCI) shares rose 3.8% to $82.33, showing positive momentum in the market. The stock has traded within a 52-week ra

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Service Corporation International (NYSE: SCI) announced it expects to issue a press release with financial results for the second quarter 2026 on Wednesday, July 29, 2026. A conference call will be hosted by SCI Management on Thursday, July 30, 2026. Details of the conference call are as follows: 

What:

Service Corporation International Second Quarter 2026 Earnings Conference Call

When:

Thursday, July 30, at 8:00 a.m. Central Time

How:

Dial-In Numbers – (888) 317-6003 or International callers at (412) 317-6061 /
Code – 7565620 or listen live via the internet through our website at www.sci-corp.com
in the Investors section under "Webcasts and Events"

Replay:

(855) 669-9658, International callers at (412) 317-0088, Code – 1797873

available through August 6, 2026, and the webcast for at least 90 days through our

website at www.sci-corp.com in the Investors section under "Webcasts and Events"

Contact:

Sandy Bobo at (713) 525-5395

About Service Corporation International

Service Corporation International (NYSE: SCI), headquartered in Houston, Texas, is North America's leading provider of funeral, cemetery and cremation services, as well as final-arrangement planning in advance, serving approximately 700,000 families each year. Our diversified portfolio of brands provides families and individuals a full range of choices to meet their needs, from simple cremations to full life celebrations and personalized remembrances. Our Dignity Memorial® brand is the name families turn to for professionalism, compassion, and attention to detail that is second to none. At June 30, 2026, we owned and operated 1,495 funeral service locations and 505 cemeteries (of which 316 are combination locations) in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico. For more information about Service Corporation International, please visit our website at www.sci-corp.com. For more information about Dignity Memorial®, please visit www.dignitymemorial.com.

SOURCE Service Corporation International

-

Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration

Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine® in the treatment of head and neck cancer in Saudi Arabia with option to extend to Gulf Cooperation Council countries

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the successful conclusion of a formal signing ceremony with Saudi Amarox (“Amarox”) during the BIO International Convention 2026 on June 22nd in San Diego, marking a significant step forward in U.S.–Saudi cooperation in healthcare innovation and oncology.

“International collaboration has been central to CEL-SCI's development strategy for many years, and we look forward to contributing our experience and expertise to support oncology care throughout the region," said Geert Kersten, Chief Executive Officer.

Share The ceremony brought together executives from CEL-SCI and Amarox, along with representatives from Saudi healthcare, investment, and trade organizations, highlighting the growing partnership between the U.S. and the Kingdom of Saudi Arabia in advancing medical innovation and improving patient care.

Under the agreement, Amarox will support activities related to the planned introduction and commercialization of Multikine®* in Saudi Arabia and potentially other counties in the region, subject to regulatory approvals.

"We are pleased to work with Amarox and our Saudi partners as Saudi Arabia continues to invest in healthcare innovation and advanced medical technologies,” said Geert Kersten, Chief Executive Officer of CEL-SCI. “International collaboration has been central to CEL-SCI's development strategy for many years, and we look forward to contributing our experience and expertise to support oncology care throughout the region."

CEL-SCI conducted the world's largest Phase 3 trial in newly diagnosed advanced head and neck cancer, enrolling 928 patients across 23 countries, three continents, and approximately 100 clinical sites. The scale and geographic diversity of the study underscore CEL-SCI's role as an international oncology innovator and its commitment to advancing cancer care through global scientific cooperation.

Abdullah Alzomaie, CEO and Founder of Amarox, commented, "Saudi Arabia is investing significantly in healthcare transformation and access to innovative medicines. We believe this collaboration supports those objectives while strengthening international partnerships that can help bring promising therapies to patients throughout the Kingdom and the broader region."

Saudi Arabia's Vision 2030 initiative places significant emphasis on healthcare modernization, innovation, and international collaboration. The Kingdom has made substantial investments in healthcare infrastructure, biotechnology, pharmaceutical development, and research capabilities as it expands its regional center for advanced healthcare and life sciences.

About Multikine

Multikine is a cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

About Head and Neck Cancer

Head and neck cancer is the 6th most common cancer, with approximately 900,000 newly diagnosed cases per year globally. The newly diagnosed stage 3 and 4 patients with this cancer represent a severe unmet need.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

More News From CEL-SCI Corporation

Back to Newsroom

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $2.5 million.

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the sole placement agent for the offering.

The securities were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025 and declared effective on August 12, 2025. The offering was made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

Service Corp. (SCI - Free Report) came out with quarterly earnings of $0.97 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -3.24%. A quarter ago, it was expected that this funeral home and cemetery operator would post earnings of $1.14 per share when it actually produced earnings of $1.14, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Service Corp., which belongs to the Zacks Funeral Services industry, posted revenues of $1.1 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.82%. This compares to year-ago revenues of $1.07 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Service Corp. shares have added about 10.8% since the beginning of the year versus the S&P 500's gain of 4.3%.

What's Next for Service Corp.?While Service Corp. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Service Corp. was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.97 on $1.1 billion in revenues for the coming quarter and $4.19 on $4.44 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Funeral Services is currently in the bottom 7% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Carriage Services (CSV - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 6.

This provider of funeral and cemetary services and products is expected to post quarterly earnings of $0.85 per share in its upcoming report, which represents a year-over-year change of -11.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Carriage Services' revenues are expected to be $111.41 million, up 4.1% from the year-ago quarter.

Key Takeaways SCI Q1 EPS missed estimates, while revenues rose 2.1% to $1,096.5M. SCI funeral services fell to 93,686; gross margin dropped to 21.2% despite higher pricing. SCI cemetery revenues grew to $465.9M; preneed sales production rose 10%, and cash flow hit $334.5M. Service Corporation International (SCI - Free Report) posted results for the first quarter of 2026, wherein earnings missed estimates as funeral volumes normalized from an unusually strong prior-year flu season, partly offset by resilient pricing, disciplined cost control and solid cemetery preneed momentum.

The company’s adjusted earnings of 97 cents per share rose 1% year over year while missing the Zacks Consensus Estimate of $1.00. Revenues increased 2.1% year over year to $1,096.5 million and beat the consensus mark of $1,088 million. Comparable cemetery preneed sales production rose 10% in the quarter, helping offset softer funeral volumes.

SCI generated operating income of $243.8 million in the first quarter of 2026, down from $251.7 million a year ago.

SCI’s Funeral Results Weaken on Volume DeclinesThe Zacks Rank #4 (Sell) company’s funeral segment faced a volume-driven headwind in the quarter. Total funeral revenues were $630.6 million versus $639.5 million in the first quarter of 2025, reflecting lower activity across core and non-funeral home channels.

Profitability in the segment also softened. Funeral gross profit fell to $134 million from $154 million, with gross margin contracting to 21.2% from 24.1%. Funeral services performed declined to 93,686 from 97,854, though average revenue per service increased to $5,919 from $5,748.

Comparable funeral revenues decreased to $620.2 million from $637.6 million, as core volumes moved lower. Comparable gross profit declined to $132.6 million from $155.4 million, and the comparable gross margin compressed to 21.4% from 24.4%, highlighting the impact of lower revenues across a high fixed-cost structure.

Service trends were mixed across categories. Comparable atneed services performed were 47,978 compared with 52,187 a year ago, while matured preneed services were 28,509 versus 29,724. Even with fewer services, total comparable average revenue per service rose to $5,947 from $5,754, and the core cremation rate edged up to 57.8% from 57.4%.

SCI’s Cemetery Segment Delivers Strong GrowthService Corporation’s cemetery segment was the quarter’s clear bright spot. Cemetery revenues increased to $465.9 million from $434.7 million in the year-ago quarter, supported by higher recognized preneed property revenues of $209.6 million versus $188.7 million, and higher recognized preneed merchandise and service revenues of $106.3 million versus $98.5 million.

Margin performance improved alongside growth. Cemetery gross profit rose to $152.5 million from $137.4 million, and gross margin expanded to 32.7% from 31.6%, reflecting favorable operating leverage as recognized preneed activity increased.

Comparable cemetery revenues rose to $465.5 million from $434.7 million, driven by higher core revenues of $424.7 million versus $399.5 million and higher other revenue of $40.8 million versus $35.2 million. Comparable gross profit grew to $152.5 million from $137.5 million, and the comparable gross profit percentage improved to 32.8% from 31.6%.

Comparable cemetery preneed sales production increased to $356.2 million from $324.6 million, while total preneed and atneed sales production rose to $466.5 million from $437.8 million. The recognition rate was 91% compared with 91.3% in the prior-year quarter.

SCI’s 2026 View Reaffirmed, Cash Flow ImprovesService Corporation’s adjusted operating cash flow increased to $334.5 million for the first quarter, driven by favorable working capital movements. Total capital expenditures were $79.9 million compared with $78.2 million a year ago, reflecting continued investment in field locations, cemetery development and growth projects.

SCI ended the quarter with cash and cash equivalents of roughly $258 million, while long-term debt was nearly $5.11 billion.

Management reaffirmed 2026 guidance for diluted earnings per share excluding special items of $4.05-$4.35 and net cash provided by operating activities excluding special items of $1.005-$1.065 billion, with maintenance capital expenditures expected to total $325 million.

Shares of SCI have risen 10.8% year to date, in line with the industry.

Consumer Staple Stocks to ConsiderSmithfield Foods, Inc. (SFD - Free Report) produces various packaged meats and fresh pork products in the United States and internationally. It carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Smithfield Foods’ current financial-year sales and earnings indicates growth of 1.3% and 7.5%, respectively, from the prior-year reported levels. SFD delivered a trailing four-quarter earnings surprise of 12%, on average.

Tyson Foods, Inc. (TSN - Free Report) operates as a food company through the Beef, Pork, Chicken and Prepared Foods segments. TSN currently carries a Zacks Rank #2.

The Zacks Consensus Estimate for Tyson Foods’ current fiscal-year sales calls for growth of 4.4%, while the consensus mark for earnings indicates a decline of 4.1% from the year-ago figures. TSN delivered a trailing four-quarter earnings surprise of 16.5%, on average.

Post Holdings (POST - Free Report) operates as a consumer-packaged goods holding company. At present, POST carries a Zacks Rank of 2. Post Holdings delivered a trailing four-quarter earnings surprise of 19.6%, on average.

The consensus estimate for Post Holdings’ current fiscal-year sales and earnings implies growth of 2.7% and 0.1%, respectively, from the year-ago figures.

Friday, 01 May 2026 09:29 AM

Topic: 

Earnings COLUMBUS, OH / ACCESS Newswire / May 1, 2026 / SCI Engineered Materials, Inc. ("SCI" or "Company") (OTCQB:SCIA), today reported financial results for the three months ended March 31, 2026.

Jeremy Young, President and Chief Executive Officer, stated, "Our 2026 first quarter financial performance included record revenue, and significantly higher gross profit, net income, and quarter-end order backlog compared to the same period a year ago. We are especially encouraged by increased sales of products introduced in 2025 and additional specialty services that complement SCI's established capabilities. Customer interest in a domestic manufacturer continues to increase."

Mr. Young added, "SCI's marketing and sales initiatives continue to enhance the Company's visibility which resulted in the addition of new customers and an increased number of inquiries being converted to orders during the first quarter of 2026. Specific benefits are attributable to participation in industry specific trade shows and expanded online marketing initiatives. These focused efforts are enabling the Company to gain traction in specific niche markets as customers recognize the breadth of our manufacturing and services portfolio."

Revenue

Revenue increased 133% for the three months ended March 31, 2026, to a record $8,160,362 compared to $3,500,232 for the same period in 2025. The year-over-year difference was due to increased cost of a key raw material, product mix and higher volume compared to a year ago.

Order backlog was $7.1 million at March 31, 2026, compared to $2.6 million at December 31, 2025, and $2.5 million on the same date a year ago, due to products introduced in 2025 and new customers. Intra-quarter orders remain strong as companies continue to effectively manage their inventories.

Gross profit

Gross profit increased 90% to $2,035,120 for the first quarter of 2026 from $1,072,814 for the first quarter of 2025, primarily due to higher revenue.

Operating expenses

Operating expenses were $1,546,196, including fraud expense of $562,026, for the first three months of 2026 compared to operating expenses of $770,275 for the same period last year. Key factors in the year-over-year comparison include the fraud expense, higher non-cash compensation and benefit expense due to timing issues, and increased staff versus the first quarter of 2025.

Fraud expense

On February 10, 2026, the Company reported it was subjected to an imposter scam of $898,325 executed in conjunction with bank fraud. The Company has recovered $336,299, resulting in a fraud expense of $562,026 recorded in the first quarter of 2026. Comprehensive efforts continue to be actively pursued to recover the funds involved.

Net interest income

Net interest income was $109,086 for the three months ended March 31, 2026, or 11% above $98,130 for the same period last year. This increase was attributable to higher cash and cash equivalents, and additional investments in marketable securities compared to the first quarter of 2025.

Income taxes

Income tax expense increased 49% to $135,748 for the three months ended March 31, 2026, from $90,952 for the same period in 2025 due to higher taxable income for the first quarter of this year. The Company's effective tax rate remained stable at 22.7% for the first quarter of 2026 and 2025, respectively.

Net income

Net income was $462,262 for the three months ended March 31, 2026, versus $309,717 for the comparable period in 2025. The 49% year-over-year increase was primarily attributable to higher gross profit. Net income per diluted share was $0.10 for the first quarter of 2026 versus $0.07 for the first quarter of 2025. Shares outstanding decreased approximately 2% for the first quarter of 2026 compared to the same period last year due to the Company's share repurchase program initiated during the fourth quarter of 2025.

Cash and cash equivalents

Cash and cash equivalents were $8,540,160 at March 31, 2026, versus $7,939,000 at December 31, 2025, an increase of 7.6%. The Company's investments in marketable securities were $3,367,688 at March 31, 2026, compared to $3,367,125 at December 31, 2025.

About SCI Engineered Materials, Inc.

SCI Engineered Materials is a global supplier and manufacturer of advanced materials for PVD thin film applications and works closely with end users and OEMs to develop innovative, customized solutions. Additional information is available at www.sciengineeredmaterials.com or follow SCI Engineered Materials, Inc. at:

https://www.linkedin.com/company/sci-engineered-materials.-inc

https://www.facebook.com/sciengineeredmaterials/

https://x.com/SciMaterials

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Those statements include, but are not limited to, all statements regarding intent, beliefs, expectations, projections, customer guidance, forecasts, plans of the Company and its management. These forward-looking statements involve numerous risks and uncertainties, including without limitation, other risks and uncertainties detailed from time to time in the Company's Securities and Exchange Commission filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025. One or more of these factors has affected and could affect the Company's projections in the future. Therefore, there can be no assurances that the forward-looking statements included in this press release will prove to be accurate. Due to the significant uncertainties in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company, or any other persons, that the objectives and plans of the Company will be achieved. All forward-looking statements made in this press release are based on information presently available to the management of the Company. The Company assumes no obligation to update any forward-looking statements.

SCI ENGINEERED MATERIALS, INC.
CONDENSED BALANCE SHEETS

ASSETS

March 31,

December 31,

2026

2025

(UNAUDITED)

Current Assets

Cash and cash equivalents

$

8,540,160

$

7,939,000

Investments - marketable securities, short term

298,688

298,125

Accounts receivable, less allowance for doubtful accounts

787,910

720,364

Inventories

3,277,395

1,091,471

Prepaid purchase orders and expenses

153,158

196,491

Total current assets

13,057,311

10,245,451

Property and Equipment, at cost

10,937,753

10,854,986

Less accumulated depreciation and amortization

(7,899,596

)

(8,020,249

)

Property and equipment, net

3,038,157

2,834,737

Investments, net - marketable securities, long term

3,069,000

3,069,000

Right of use asset, net

1,011,287

1,061,709

Other assets

60,227

61,461

Total other assets

4,140,514

4,192,170

TOTAL ASSETS

$

20,235,982

$

17,272,358

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities

Operating lease, short term

$

222,253

$

212,561

Accounts payable

266,258

245,523

Customer deposits

3,556,441

829,158

Accrued expenses

427,060

568,503

Total current liabilities

4,472,012

1,855,745

Deferred tax liability

515,154

389,572

Operating lease, long term

789,032

849,148

Total liabilities

5,776,198

3,094,465

Total shareholders' equity

14,459,784

14,177,893

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

20,235,982

$

17,272,358

SCI ENGINEERED MATERIALS, INC
STATEMENTS OF INCOME
(UNAUDITED)

THREE MONTHS ENDED MARCH 31,

2026

2025

Revenue

$

8,160,362

$

3,500,232

Cost of revenue

6,125,242

2,427,418

Gross profit

2,035,120

1,072,814

General and administrative expense

642,043

547,821

Fraud expense

562,026

-

Research and development expense

142,610

102,267

Marketing and sales expense

199,517

120,187

Income from operations

488,924

302,539

Interest income, net

109,086

98,130

Income before provision for income taxes

598,010

400,669

Income tax expense

135,748

90,952

NET INCOME

$

462,262

$

309,717

Earnings per share - basic and diluted

Income per common share

Basic

$

0.10

$

0.07

Diluted

$

0.10

$

0.07

Weighted average shares outstanding

Basic

4,470,227

4,568,127

Diluted

4,470,227

4,572,491

SCI ENGINEERED MATERIALS, INC
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

THREE MONTHS ENDED MARCH 31,

2026

2025

CASH PROVIDED BY (USED IN):

Operating activities

$

1,177,642

$

933,353

Investing activities

(308,982

)

(333,336

)

Financing activities

(267,500

)

-

NET INCREASE IN CASH

601,160

600,017

CASH - Beginning of period

7,939,000

6,753,403

CASH - End of period

$

8,540,160

$

7,353,420

Contact: Robert Lentz
(614) 439-6006

SOURCE: SCI Engineered Materials, Inc

Service Corporation International (SCI) Presents at Oppenheimer 21st Annual Industrial Growth Virtual Conference Transcript

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.

A month has gone by since the last earnings report for Service Corp. (SCI - Free Report) . Shares have lost about 5.9% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Service Corp. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Service Corporation Q1 Earnings Miss on Lower Funeral VolumesService Corporation posted adjusted earnings of 97 cents per share, which rose 1% year over year while missing the Zacks Consensus Estimate of $1.00. Revenues increased 2.1% year over year to $1,096.5 million and beat the consensus mark of $1,088 million. Comparable cemetery preneed sales production rose 10% in the quarter, helping offset softer funeral volumes.

SCI generated operating income of $243.8 million in the first quarter of 2026, down from $251.7 million a year ago.

SCI’s Funeral Results Weaken on Volume DeclinesThe company’s funeral segment faced a volume-driven headwind in the quarter. Total funeral revenues were $630.6 million versus $639.5 million in the first quarter of 2025, reflecting lower activity across core and non-funeral home channels. Profitability in the segment also softened. Funeral gross profit fell to $134 million from $154 million, with gross margin contracting to 21.2% from 24.1%. Funeral services performed declined to 93,686 from 97,854, though average revenue per service increased to $5,919 from $5,748.

Comparable funeral revenues decreased to $620.2 million from $637.6 million, as core volumes moved lower. Comparable gross profit declined to $132.6 million from $155.4 million, and the comparable gross margin compressed to 21.4% from 24.4%, highlighting the impact of lower revenues across a high fixed-cost structure.

Service trends were mixed across categories. Comparable atneed services performed were 47,978 compared with 52,187 a year ago, while matured preneed services were 28,509 versus 29,724. Even with fewer services, total comparable average revenue per service rose to $5,947 from $5,754, and the core cremation rate edged up to 57.8% from 57.4%.

SCI’s Cemetery Segment Delivers Strong GrowthService Corporation’s cemetery segment was the quarter’s clear bright spot. Cemetery revenues increased to $465.9 million from $434.7 million in the year-ago quarter, supported by higher recognized preneed property revenues of $209.6 million versus $188.7 million, and higher recognized preneed merchandise and service revenues of $106.3 million versus $98.5 million.
Margin performance improved alongside growth. Cemetery gross profit rose to $152.5 million from $137.4 million, and gross margin expanded to 32.7% from 31.6%, reflecting favorable operating leverage as recognized preneed activity increased.

Comparable cemetery revenues rose to $465.5 million from $434.7 million, driven by higher core revenues of $424.7 million versus $399.5 million and higher other revenue of $40.8 million versus $35.2 million. Comparable gross profit grew to $152.5 million from $137.5 million, and the comparable gross profit percentage improved to 32.8% from 31.6%.

Comparable cemetery preneed sales production increased to $356.2 million from $324.6 million, while total preneed and atneed sales production rose to $466.5 million from $437.8 million. The recognition rate was 91% compared with 91.3% in the prior-year quarter.

SCI’s 2026 View Reaffirmed, Cash Flow ImprovesService Corporation’s adjusted operating cash flow increased to $334.5 million for the first quarter, driven by favorable working capital movements. Total capital expenditures were $79.9 million compared with $78.2 million a year ago, reflecting continued investment in field locations, cemetery development and growth projects. SCI ended the quarter with cash and cash equivalents of roughly $258 million, while long-term debt was nearly $5.11 billion.

Management reaffirmed 2026 guidance for diluted earnings per share excluding special items of $4.05-$4.35 and net cash provided by operating activities excluding special items of $1.005-$1.065 billion, with maintenance capital expenditures expected to total $325 million.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -10.36% due to these changes.

VGM ScoresAt this time, Service Corp. has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Service Corp. has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

, /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today announced that its Board of Directors has increased the authorized level of repurchases of its common stock by approximately $472 million.  When combined with approximately $128 million of authority remaining under the existing program, this represents a total of $600 million of current share repurchase authority effective today.

Cautionary Statement on Forward-Looking Statements

The statements in this press release that are not historical facts are forward-looking statements.  These forward-looking statements have been made in reliance on the "safe harbor" protections provided under the Private Securities Litigation Reform Act of 1995.  These statements may be accompanied by words such as "believe," "estimate," "project," "expect," "anticipate," or "predict," that convey the uncertainty of future events or outcomes.  These statements are based on assumptions that we believe are reasonable; however, many important factors could cause our actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of us.  There can be no assurance that future dividends will be declared.  The actual declaration of future dividends, and the establishment of record and payment dates, is subject to final determination by our Board of Directors each quarter after its review of our financial performance.  Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, restrictions on the payment of dividends under existing or future credit agreements or other financing arrangements; changes in tax laws relating to corporate dividends; a determination by the Board of Directors that the declaration of a dividend is not in the best interests of the Company and its shareholders; an increase in our cash needs or a decrease in available cash; or a deterioration in our financial condition or results.  For further information on these and other risks and uncertainties, see our Securities and Exchange Commission filings, including our 2025 Annual Report on Form 10-K.  Copies of this document as well as other SEC filings can be obtained from our website at http://www.sci-corp.com.  We assume no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by us, whether as a result of new information, future events or otherwise.

About Service Corporation International

Service Corporation International (NYSE: SCI), headquartered in Houston, Texas, is North America's leading provider of funeral, cemetery and cremation services, as well as final-arrangement planning in advance, serving approximately 700,000 families each year.  Our diversified portfolio of brands provides families and individuals a full range of choices to meet their needs, from simple cremations to full life celebrations and personalized remembrances.  Our Dignity Memorial® brand is the name families turn to for professionalism, compassion, and attention to detail that is second to none.  At March 31, 2026, we owned and operated 1,487 funeral service locations and 503 cemeteries (of which 314 are combination locations) in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico.  For more information about Service Corporation International, please visit our website at www.sci-corp.com.  For more information about Dignity Memorial®, please visit www.dignitymemorial.com.

For additional information contact:  [email protected]

Investors:

Trey Bocage – Assistant Vice President / Treasury and Investor Relations

(713) 525-3454

Andrea Low – Director / Federal Tax and Investor Relations

(713) 525-2811

Media:

Jay Andrew – Assistant Vice President / Corporate Communications

(713) 525-3468

SOURCE Service Corporation International